Clinical Trials Logo

Filter by:
NCT ID: NCT06444880 Not yet recruiting - Clinical trials for SMARCB1-Deficient Malignancies

Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies

Start date: November 29, 2024
Phase: Phase 2
Study type: Interventional

To find out if ubamatamab, given by itself or in combination with cemiplimab, can help to control the disease in participants with renal medullary carcinoma (RMC) and epithelioid sarcoma (ES).

NCT ID: NCT06444841 Not yet recruiting - Alzheimer Disease Clinical Trials

Paper-Based and Smartphone-Based Memory Supports

Start date: June 1, 2024
Phase: N/A
Study type: Interventional

Alzheimer's disease and related dementias lead to marked declines in daily functioning, independence, and quality of life. One of the earliest cognitive changes in these conditions is impairment in prospective memory, or the ability to remember future intentions such as taking medications at a given time. Prior intervention studies that targeted prospective memory used mnemonic strategies or cognitive training, but these approaches resulted in modest gains in clinical populations. By contrast, a Stage I pilot trial indicated that smartphone-based memory aids (reminder apps) can be accepted and used by persons with mild cognitive impairment and mild dementia to improve both subjective and objective prospective memory performance. The investigators will now test for efficacy, durability, and generalizability of benefits across diverse samples in a Stage II randomized controlled trial. Some 200 participants with mild cognitive impairment or mild dementia will be recruited, half of whom will be from digitally-disadvantaged backgrounds (low socioeconomic status, rural, or historically underrepresented groups). Participants will complete baseline assessments and then be randomly assigned to a smartphone reminder app intervention or an active control condition that uses a paper- based memory support system. Across a 4-week intervention period, participants will complete patient-selected and experimenter-assigned prospective memory assessments and receive booster training sessions to promote self-efficacy with the intervention/control system. Durability of effects will be assessed at 3-month and 6-month follow-up sessions. As a secondary aim, study partners will be simultaneously enrolled to collect informant ratings, track how much study partners assist the participants, and determine whether improving prospective memory in patients improves quality of life in study partners (e.g., by reducing the double to-do list burden of remembering for themselves and for care recipients). As a third aim, the investigators will identify barriers and facilitators to smartphone interventions in digitally-disadvantaged individuals who have historically been underrepresented in technology and dementia research.

NCT ID: NCT06444594 Not yet recruiting - Aging Clinical Trials

Transient Receptor Potential Channels

TRP
Start date: June 15, 2024
Phase: Early Phase 1
Study type: Interventional

Neurovascular signaling in the skin associated with stimulation of the transient receptor potential (TRP) channels. These channels are stimulated by both temperature and naturally occurring bioactive agents found in mint, chili peppers, garlic, etc. The aim of the study is to examine how topically applied TRP channel agonists including menthol, capsaicin and camphor impact neurovascular responses in the skin.

NCT ID: NCT06444542 Not yet recruiting - Colo-rectal Cancer Clinical Trials

Understanding Patient Preference on Colorectal Cancer Screening Options-PSU

U-Screen
Start date: May 25, 2024
Phase:
Study type: Observational

There are significant barriers to colorectal cancer screening within underserved populations due to the cost, accessibility, and acceptability of screening methods. Patient-friendly approaches that minimize stress and discomfort for the patient are needed to enhance screening compliance and achieve an early diagnosis. The primary aim of this study is to examine whether the availability of a blood-based screening option, which can be done at the point of service and is familiar to patients, will improve patient compliance to recommended CRC screening

NCT ID: NCT06444529 Not yet recruiting - Ocular Redness Clinical Trials

A Double-Masked Comparison of FID 123320 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness

Start date: August 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of Apraclonidine Hydrochloride Ophthalmic Solution 0.125% when compared to Vehicle, in relieving redness of the eye due to minor eye irritations. This study will be conducted in the United States.

NCT ID: NCT06444516 Not yet recruiting - Dry Eye Disease Clinical Trials

Study of Safety and Performance of a Novel Ocular Lubricant in Subjects With Dry Eye Disease

Start date: August 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate and demonstrate the efficacy and safety of an investigational ocular lubricant formulation in patients with mild to moderate dry eye disease (DED).

NCT ID: NCT06444464 Not yet recruiting - Clinical trials for Overweight and Obesity

The BEE-Power Study (Boosting Exercise for Excellent Pediatric Blood Pressure)

Start date: July 1, 2024
Phase: N/A
Study type: Interventional

The goal of this study is to compare two types of exercises, isometric exercise (like squats and planks) and aerobic exercise (such as running), to see which one is more effective at improving blood pressure in teenagers aged 13 to 17.5 years. The main question the study aims to answer is: - Do the effects of one session of isometric exercise on the blood pressure of adolescents compare to the effects of one session of aerobic exercise? Adolescents diagnosed with high blood pressure may qualify for this study. Participants will be randomly assigned to either a single session of isometric exercise or a single session of aerobic exercise. - Participants will attend 3 study visits in total. - Study visits should be completed within 4 weeks of enrollment. - At the initial visit, samples (example: blood) will be collected and body measurements will be taken. - Participants will be asked to answer questionnaires (diet, growth, and others) - At visit 2, participants will have their blood pressure measured using a 24 hour blood pressure monitor. - At visit 3, participants will participate in a single session of either aerobic or isometric exercise. They will wear a 24-hour blood pressure monitor immediately after the exercise session.

NCT ID: NCT06444412 Not yet recruiting - WHO Grade 3 Glioma Clinical Trials

An Investigational Scan (Ga-68 PSMA-11 PET/CT) for Detection of Disease Recurrence or Progression in Patients With Glioma

Start date: August 1, 2024
Phase: Phase 2
Study type: Interventional

This clinical trial evaluates whether gallium-68 (Ga-68) prostate specific membrane antigen (PSMA)-11 positron emission tomography (PET)/computed tomography (CT) imaging is useful in differentiating between disease that has come back after a period of improvement (recurrence) or that is growing, spreading, or getting worse (progression) and treatment effect in patients with glioma. Patients with glioma undergo frequent imaging for assessment of disease status. After first-line treatment however, the correlation between imaging findings and tumor activity can be confused, and surgery is often required for definitive diagnosis. The PET/CT scanner is an imaging machine that combines 2 types of imaging in a single scan. The PET scanner detects and takes pictures of where the radioactive imaging agent (68Ga PSMA-11) has gone in the body and the CT scanner uses x-rays to take structural pictures inside the body. PSMA PET also binds to neoplastic blood vessels, including those in gliomas. This study may help researchers learn whether GA-68 PSMA-11 PET/CT is useful for improving detection of tumor recurrence or progression, as opposed to treatment effects, in patients with gliomas.

NCT ID: NCT06444399 Not yet recruiting - Clinical trials for Pityriasis Rubra Pilaris

Deucravacitinib (BMS-986165) for Pityriasis Rubra Pilaris

Start date: July 1, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of Deucravacitinib (BMS-986165) in Pityriasis Rubra Pilaris as assessed by the change in Investigator Global Assessment (IGA), PASI- 50, 75, 90, DLQI, NRS itch, and Skindex-16 at week 24. To predict responses through the identification of unique biomarkers of PRP utilizing single-cell RNA sequencing.

NCT ID: NCT06444360 Not yet recruiting - HIV Clinical Trials

Behavioral Activation and Risk Reduction for Stimulant Use Among Sexually Active Young Gay/Bisexual Minority Men (IMPACT)

IMPACT
Start date: July 22, 2024
Phase: N/A
Study type: Interventional

The use of behavioral intervention to reduce stimulant use and concurrent HIV sexual transmission risk